Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Moderna (NASDAQ:MRNA) shares dropped on Wednesday after the latest efficacy data for its newly ... GSK (GSK) and Pfizer (PFE) currently dominate the market for RSV vaccines after the FDA approved ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

1 lineage of Omicron but is already being superseded by sister strain KP.3. Still, Pfizer/BioNTech and Moderna say they expect their new vaccines will retain protective efficacy as the two strains ...

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ... justifying a "hold" position rather than a "sell.". Moderna (NASDAQ:MRNA), which went public at $22 in 2018 ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.